BBOT BridgeBio Oncology Therapeutics, Inc. Common Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

BBOT — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.2B
Employees
88
List Date
2025-08-12
CIK
0001869105
Next Earnings
2026-11-11
EPS Forecast
($0.65) (8 est.)
Headquarters
South San Francisco, CA
Homepage
https://www.bridgebio.com

BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'25'26Avg
Jan---4.64%-4.64%
Feb---16.63%-16.63%
Mar---11.21%-11.21%
Apr---6.87%-6.87%
May--6.91%6.91%
Jun---10.88%-10.88%
Jul--4.59%4.59%
Aug-7.36%6.67%-0.35%
Sep20.88%-53.51%-16.31%
Oct-0.75%-32.99%*-16.87%
Nov0.16%--0.16%
Dec2.54%--2.54%
Total14.15%-78.23%-32.04%
* Only 2 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $3.22
SMA 50: $5.52
SMA 200: $8.33
Current: $2.64
EMA 12: $2.95
EMA 26: $3.68
MACD: -0.7365 | Signal: 0.1022
BEARISH
ADX (14): 59.19
STRONG TREND
+DI: 8.62
−DI: 34.58

Momentum Oscillators

RSI (14): 19.79
OVERSOLD
Stoch %K: 8.35
Stoch %D: 7.32
Williams %R: -95.88

Volume & Volatility

BB Upper: $4.16
BB Lower: $2.28
NEUTRAL
OBV: -12,423,920
Vol SMA 20: 596,927
Vol ROC: 106.47%
ATR: $0.27
True Range: $0.07
HV 20: 62.9%
HV 30: 60.6%
HV 60: 88.9%

Data Summary

Data Points: 304
Last Updated:
Date Range: 2025-08-12T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report: BBOT

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers and Primary Risks:

  • Positive recent news headlines, including poster presentations at the San Antonio Breast Cancer Symposium and preclinical data presented at the AACR-NCI-EORTC International Conference
  • High volatility, with beta of 1.25 relative to SPY
  • Technical signals indicate a range-bound market, with no clear trend direction

Investment Thesis:

BBOT presents an attractive opportunity for investors seeking exposure to the biotech sector. The recent positive news headlines have sparked interest in the company's pipeline and potential therapeutic applications. However, high volatility and lack of clear trend direction make it essential to implement risk management strategies.

Recent News Sentiment Impact:

The recent news headlines are predominantly positive, with two presentations at prominent medical conferences highlighting the potential of BBOT's RAS:PI3Kα breaker. This sentiment has contributed to a 5% price increase over the past week.

Technical Analysis

Trend Direction: Range-bound (Short-term), Neutral (Medium-term), and Bearish (Long-term)

Support/Resistance Levels:

  • Resistance: $9.14 (Upper Bollinger Band)
  • Support: $8.40 (SMA 20) and $7.67 (Lower Bollinger Band)

Momentum Signals:

  • RSI: Neutral (48.80), indicating no clear buy or sell signal
  • MACD: Bearish, with the histogram below the zero line (-0.14)
  • Stochastic %K and %D: Overbought, but not excessively so

Volume Analysis:

  • Volume SMA 20: Increasing trend, indicating institutional interest
  • OBV: Upward trend, suggesting accumulation
  • Volume Rate of Change: High, indicating high trading activity

News & Sentiment Analysis

Recent Headlines Summary: Positive news headlines from medical conferences, highlighting the potential of BBOT's pipeline.

Sentiment Assessment: Neutral (Positive/Negative/Neutral)

Catalyst Identification: Upcoming investor healthcare conferences and potential future presentations at medical conferences.

Market Narrative: The market narrative is influenced by positive recent news headlines, which has contributed to a short-term uptrend. However, the long-term trend remains bearish due to the high volatility.

Risk & Volatility Assessment

Beta Interpretation: High risk (1.25), as the stock moves more than the broader market.

Volatility Regime: Current regime is high volatility, with historical volatility at 56%.

Options Market Signals: No options data available.

Downside Protection: Support levels are $8.40 (SMA 20) and $7.67 (Lower Bollinger Band).

Market Context & Positioning

Sector Performance: Biotech sector is performing relatively well, with a small-cap biotech ETF up 5% over the past month.

Institutional Activity: Institutional interest is increasing, as reflected in the volume SMA 20 and OBV trends.

Correlation Analysis: The stock's correlation with SPY is low (0.22), indicating it is not highly correlated with the broader market.

Relative Valuation: BBOT is trading within its historic range, with a relative strength index of 56%.

Key Levels & Action Items

Critical Price Levels:

  • Resistance: $9.14 (Upper Bollinger Band)
  • Support: $8.40 (SMA 20) and $7.67 (Lower Bollinger Band)

Breakout/Breakdown Levels: No clear breakout or breakdown levels identified.

Time-Sensitive Catalysts: Upcoming investor healthcare conferences and potential future presentations at medical conferences.

Risk Management: Implement stop-loss levels below support ($8.40) and consider position sizing adjustments based on the high volatility.

By analyzing the technical indicators, news headlines, and risk metrics, we can conclude that BBOT presents a neutral investment opportunity with moderate risk. The recent positive news headlines have contributed to an uptrend, but the long-term trend remains bearish due to high volatility. Investors should consider implementing risk management strategies and monitor key levels and catalysts for potential trading opportunities.

Generated
News
All BBOT news →

BBOT Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 1.4536
Alpha: -136.48%
Correlation: 0.2647
R-Squared: 7.0%
Stock Volatility: 70.0%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time

BBOT Institutional Ownership (13F)

Latest filings — 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

70 filers59,971,554 shares$460.42M value
# Filer Shares Value % of Total % of Float Period
1 Cormorant Asset Management, LP 17,878,594 $136.23M 29.59% — 2026-06-30
2 DEERFIELD MANAGEMENT COMPANY, L.P. 4,885,446 $37.23M 8.09% — 2026-06-30
3 Omega Fund Management, LLC 3,289,661 $25.07M 5.44% — 2026-06-30
4 EcoR1 Capital, LLC 2,823,126 $21.51M 4.67% — 2026-06-30
5 Alphabet Inc. 2,823,126 $21.51M 4.67% — 2026-06-30
6 Wellington Management Group LLP Custodian 2,789,302 $21.25M 4.62% — 2026-06-30
7 Enavate Sciences GP, LLC 2,626,946 $20.02M 4.35% — 2026-06-30
8 Citadel Advisors LLC Custodian 2,617,827 $19.95M 4.33% — 2026-06-30
9 Novo Holdings A/S 2,250,000 $17.14M 3.72% — 2026-06-30
10 BlackRock, Inc. Custodian 2,154,040 $16.41M 3.56% — 2026-06-30
11 Vanguard Capital Management LLC 2,005,649 $15.28M 3.32% — 2026-06-30
12 Laurion Capital Management LP 2,002,701 $15.26M 3.31% — 2026-06-30
13 ARMISTICE CAPITAL, LLC 1,764,000 $13.44M 2.92% — 2026-06-30
14 Vanguard Group Inc Custodian 791,095 $9.90M 2.15% — 2025-12-31
15 State Street Corp 1,036,569 $7.90M 1.72% — 2026-06-30
16 Aisling Capital Management LP 1,018,018 $7.76M 1.68% — 2026-06-30
17 Opaleye Management Inc. 700,000 $5.33M 1.16% — 2026-06-30
18 Geode Capital Management, LLC Custodian 622,351 $4.74M 1.03% — 2026-06-30
19 Granahan Investment Management, LLC 558,526 $4.26M 0.92% — 2026-06-30
20 SPHERA FUNDS MANAGEMENT LTD. 460,985 $3.51M 0.76% — 2026-06-30
21 ADAGE CAPITAL PARTNERS GP, L.L.C. 400,000 $3.05M 0.66% — 2026-06-30
22 ROYCE & ASSOCIATES LP 384,941 $2.93M 0.64% — 2026-06-30
23 Catalio Capital Management, LP 318,407 $2.43M 0.53% — 2026-06-30
24 T. Rowe Price Associates, Inc. 300,000 $2.29M 0.50% — 2026-06-30
25 Vanguard Fiduciary Trust Co 291,522 $2.22M 0.48% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

BBOT Insider Trading (Form 4)

Latest: 2026-10-23
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-23 Marc Cobo Principal Accounting Officer Tax (F) −203 $2.68 -$544 EDGAR
2026-10-05 Marc Cobo Principal Accounting Officer Tax (F) −126 $3.94 -$496 EDGAR
2026-10-05 Pedro Beltran President and CEO Tax (F) −1,047 $3.94 -$4.1K EDGAR
2026-10-05 Idan Elmelech COO & Principal Financial Ofcr Tax (F) −343 $3.94 -$1.4K EDGAR
2026-10-05 Yong Ben Chief Med & Dev Officer Tax (F) −1,047 $3.94 -$4.1K EDGAR
2026-09-14 Marc Cobo Principal Accounting Officer Mixed +8,835 $5.52 -$1.1K EDGAR
2026-07-06 Marc Cobo Principal Accounting Officer Tax (F) −125 $7.80 -$975 EDGAR
2026-07-06 Yong Ben Chief Med & Dev Officer Tax (F) −1,047 $7.80 -$8.2K EDGAR
2026-07-06 Pedro Beltran President and CEO Tax (F) −1,047 $7.80 -$8.2K EDGAR
2026-07-06 Bihua Chen Director Other (J) 4,528,186 (reclass) — EDGAR
2026-07-06 Idan Elmelech COO & Principal Financial Ofcr Tax (F) −343 $7.80 -$2.7K EDGAR
2026-06-18 Raymond J. Kelleher Director Grant (A) +31,675 opt — EDGAR
2026-06-18 Peter F Lebowitz Director Grant (A) +7,289 opt — EDGAR
2026-06-18 Bihua Chen Director Grant (A) +31,675 opt — EDGAR
2026-06-18 Jake Bauer Director Grant (A) +31,675 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

BBOT Insider Holdings

7 insiders · @ $2.64
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 BridgeBio Pharma, Inc. 10%+ Owner 14,589,846 $38.52M $0 1 2025-10-16
2 Bihua Chen Director 1,905,046 $5.03M $0 3 2026-07-06
3 Yong Ben Chief Med & Dev Officer 43,529 $114.9K $0 5 2026-10-05
4 Pedro Beltran President and CEO 43,529 $114.9K $0 6 2026-10-05
5 Uneek Mehra Chief Financial Officer 22,806 $60.2K $0 3 2026-05-05
6 Idan Elmelech COO & Principal Financial Ofcr 14,152 $37.4K $0 3 2026-10-05
7 Marc Cobo Principal Accounting Officer 13,812 $36.5K $0 4 2026-10-23
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

BBOT Board & Officers

As of SEC filings through Oct 23, 2026

Directors 8

Officers 4

  • Pedro Beltran · President and CEO · listed since May 2026
  • Idan Elmelech · COO & Principal Financial Ofcr · since Apr 20, 2026
  • Yong Ben · Chief Med & Dev Officer · since Aug 11, 2025
  • Marc Cobo · Principal Accounting Officer · since Apr 21, 2026

10% owners 3

Changes in the last 10 years (38)
Jun 16, 2026The company announced the departure of Michelle Doig from the board in an SEC filing
May 5, 2026Uneek Mehra reported in an SEC filing no longer being Chief Financial Officer
May 5, 2026Pedro Beltran listed as President and CEO (previously Chief Scientific Officer) in SEC filings
May 5, 2026Pedro Beltran first listed as a director in an SEC filing
Apr 27, 2026The company announced the departure of Eli M. Wallace from the board in an SEC filing
Apr 27, 2026The company announced the departure of Eli M. Wallace as Chief Executive Officer in an SEC filing
Apr 21, 2026Marc Cobo became Principal Accounting Officer
Apr 20, 2026Idan Elmelech became COO & Principal Financial Ofcr
Mar 24, 2026Peter F Lebowitz became a director
Aug 13, 2025Bihua Chen no longer listed as CEO and Chairperson in SEC filings
Aug 11, 2025Yong Ben became Chief Med & Dev Officer
Aug 11, 2025Uneek Mehra became Chief Financial Officer
Aug 11, 2025Raymond J. Kelleher became a director
Aug 11, 2025Praveen P. Tipirneni became a director
Aug 11, 2025Pedro Beltran became Chief Scientific Officer
Aug 11, 2025Neil Kumar became a director
Aug 11, 2025Nebojsa Obradovic left as Chief Legal Officer, per their own SEC filing
Aug 11, 2025Michelle Doig became a director
Aug 11, 2025Mark C. McKenna left the board, per their own SEC filing
Aug 11, 2025John P. Schmid left the board, per their own SEC filing
Not reported recently (1)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
15 ETFs hold BBOT
15 shown · $14.35M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $5.8M — 2026-09-30
2 SCHA Schwab U.S. Small-Cap ETF Nport 0.01% $2.0M — 2026-05-31
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $2.0M — 2026-09-30
4 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.02% $1.9M $10.4B 2026-10-23
5 IBB iShares Biotechnology ETF iShares (BlackRock) 0.01% $968,567 $10.7B 2026-10-23
6 CANC Tema Oncology ETF Nport 0.48% $837,251 — 2026-05-31
7 BBC Virtus Biotech Clinical Trials Etf Nport 0.70% $324,466 — 2026-07-31
8 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $246,675 — 2026-05-31
9 SGRW Harbor Active Small Cap Growth ETF Nport 0.37% $99,297 — 2026-07-31
10 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.01% $72,450 — 2026-10-26
11 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $11,249 — 2026-10-23
12 DFSU Dimensional US Sustainability Core 1 ETF Dimensional 0.00% $9,783 $2.4B 2026-10-23
13 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $7,695 — 2026-10-23
14 DFMC Dimensional US Micro Cap ETF Dimensional 0.00% $7,102 — 2026-10-23
15 PWS Pacer WealthShield ETF Nport 0.01% $3,058 — 2026-07-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.